November 10, 2015
Zenobia recalls Ground Flax Seed Meal due to salmonella
Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
November 9, 2015
Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
November 9, 2015
Cosentyx shows no further progression in joint damage in over 80% of PsA
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
November 9, 2015
Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
November 6, 2015
AstraZeneca buys ZS Pharma
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
November 6, 2015
FDA approves Genvoya
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
November 6, 2015
Sanofi and Lexicon to develop sotagliflozin (for diabetics)
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
November 5, 2015
Johnson&Johnson confimrs acquiring Novira Therapeutics
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
November 5, 2015
Quantum Pharma’s Colonis launches medical devices for side effects of cancer treatment
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
November 5, 2015
Sanofi and Hanmi in $3.5B license agreement (developing diabetes treatments)
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.